INTRODUCTION
Since the first case of pneumonia in December 2019,1 the new COVID-19 pandemic due to severe acute respiratory syndrome coronavirus 2 has spread worldwide, with an increase in critical illnesses and deaths, resulting in a lack of personal protective equipment and resources such as isolation rooms.

In addition to remdesivir plus dexamethasone, new drugs such as monoclonal antibodies and baricitinib have been developed for the treatment of COVID-19; however, the optimal therapy for COVID-19 remains uncertain.2-5 Most patients with COVID-19 experience self-limiting and/or mild symptoms, whereas certain high-risk groups experience disease progression to critical illness or death. Therefore, predicting the severity and mortality of COVID-19 is crucial in making clinical decisions for its treatment.

Several articles have been published regarding the severity and mortality of COVID-19 in specific risk groups, with older adults more likely to experience disease progression and critical illness.5,7 Patients with one or more comorbidities, such as cardiovascular disease, diabetes, dementia, and malignancy, have shown more critical illness and higher mortality rates.8,9 Various laboratory findings, such as the neutrophil-lymphocyte ratio and C-reactive protein (CRP), ferritin, and lactate dehydrogenase (LDH) levels, are well-known risk factors associated with the progression and mortality of COVID-19.6,10,11

New Scoring System for Predicting Mortality in Patients with COVID-19
Sohyun Bae, Yoonjung Kim, Soyoon Hwang, Ki Tae Kwon, Hyun-Ha Chang, and Shin-Woo Kim
Division of Infectious Diseases, Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, Korea.

Purpose: We aimed to develop a novel mortality scoring system for inpatients with COVID-19 based on simple demographic factors and laboratory findings.

Materials and Methods: We reviewed and analyzed data from patients who were admitted and diagnosed with COVID-19 at 10 hospitals in Daegu, South Korea, between January and July 2020. We randomized and assigned patients to the development and validation groups at a 70% to 30% ratio. Each point scored for selected risk factors helped build a new mortality scoring system using Cox regression analysis. We evaluated the accuracy of the new scoring system in the development and validation groups using the area under the curve.

Results: The development group included 1232 patients, whereas the validation group included 528 patients. In the development group, predictors for the new scoring system as selected by Cox proportional hazards model were age ≥70 years, diabetes, chronic kidney disease, dementia, C-reactive protein levels >4 mg/dL, infiltration on chest X-rays at the initial diagnosis, and the need for oxygen support on admission. The areas under the curve for the development and validation groups were 0.914 [95% confidence interval (CI) 0.891–0.937] and 0.898 (95% CI 0.854–0.941), respectively. According to our scoring system, COVID-19 mortality was 0.4% for the low-risk group (score 0–3) and 53.7% for the very high-risk group (score ≥11).

Conclusion: We developed a new scoring system for quickly and easily predicting COVID-19 mortality using simple predictors. This scoring system can help physicians provide the proper therapy and strategy for each patient.

Key Words: COVID-19, mortality, scoring system
Several studies have employed pre-existing scoring systems for community-acquired pneumonia or sepsis to determine COVID-19 severity. However, a scoring system for COVID-19 mortality has not yet been established, and there have been several efforts to predict COVID-19. To our knowledge, no previous study has employed comorbidities and laboratory findings, such as CRP and routine inflammatory markers, to determine COVID-19 mortality.

Therefore, this study aimed to build a scoring system for predicting COVID-19 mortality using routine tests with large samples of hospitalized patients and based on demographics, clinical characteristics, and laboratory and radiological findings.

MATERIALS AND METHODS

Patient samples and data collection
The retrospective cohort study included COVID-19 patients who were admitted to 10 hospitals in the Daegu province of South Korea between February 18 and May 19, 2020. All patients were confirmed by real-time reverse-transcriptase polymerase chain reaction assay of nasopharyngeal swabs or sputum specimens. We excluded patients who lacked laboratory findings or chest radiological findings. We followed up with the admitted patients until their discharge or death, and the last monitored date was July 30, 2020.

From the patients’ electronic medical records, we obtained data that included epidemiological characteristics, comorbidities, clinical symptoms, laboratory results, and radiological findings. Trained medical record administrators collected the data, which included laboratory findings on admission. The initial chest X-ray results were classified into two groups as no active lesion and unilateral or bilateral infiltration. The primary outcome was COVID-19 mortality during the follow-up period.

Definitions
Fever was defined as an axillary temperature above 37.5°C. All patients were classified as mild, moderate, severe, and death during hospitalization according to the worst severity score as defined in the Korean coronavirus disease 2019 response guideline version 9-5-1. Chronic heart disease included arrhythmia, cardiomyopathy, and requiring medication for coronary heart disease. Hypertension and heart failure were excluded. Neurological disease included cerebrovascular disease and hemorrhage.

Statistical analyses
We analyzed all statistical data using the R statistics version 3.1, and randomized and assigned the patients to the development and validation groups in a 70% to 30% ratio. Categorical variables are expressed as numbers and percentages, and were compared using the chi-squared test or Fisher’s exact test. Continuous variables are expressed as means ± standard deviations or medians with interquartile ranges (IQR), and were compared using the Student’s t-test or Mann-Whitney U test. CRP cutoff value was defined according to the largest Youden index rounded up to first decimal places. We employed univariate regression analyses and a Cox proportional hazards model to determine the risk factors for COVID-19 mortality in the development group. By adjusting the parameters in the development group with the Cox proportional hazards model, we matched the risk score with the potential variables. We assessed the scoring system using data within the sensitivity of the development and validation groups. We determined the sensitivity and specificity using a receiver operating characteristic (ROC) curve for the two groups, and based the optimal cutoff score on the ROC curve with optimal sensitivity and specificity and on Youden’s index (Supplementary Fig. 1, only online). We confirmed the prediction value for the new scoring system using the area under the curve (AUC). The ROC curve analysis as well as the criterion values and the coordinates of ROC curves were described using the MedCalc Statistical Software version 13.0.6 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2014). We considered a p-value < 0.05 to indicate statistical significance.

Ethics statement
The Institutional Review Boards of the 10 hospitals reviewed and approved our study protocol (approval no.: DGIRB 202007005). Considering the study’s retrospective nature and the use of anonymous clinical data for analysis, the need for informed consent was waived.

RESULTS

Patient samples and clinical findings affected COVID-19 mortality
This study enrolled a total of 2254 patients hospitalized with COVID-19. The total case fatality rate was 7.94%, and 179 patients died during hospitalization. Of the total patients, 494 were excluded due to incomplete laboratory data; 1760 patients were ultimately included and analyzed in the study. Among them, 1232 patients were randomly assigned to the development group and 528 were assigned to the validation group. Table 1 lists the demographic and clinical characteristics of the survival and non-survival subgroups in the development and validation groups. The male sex was predominant in both development and validation groups (60.9% and 69.9%, respectively), and the two groups had similar median ages [61.0 (IQR 48.0–73.0) and 61.0 (IQR 49.0–74.0), respectively]. The median ages of the non-survival subgroups were significantly greater in both groups [development group: 59.0 (IQR 46.0–71.0) vs. 78.5 (IQR 71.0–85.0), p < 0.001; validation group: 59.0 (IQR 47.0–70.0) vs. 81.0 (IQR 73.0–85.0), p < 0.001]. The proportion of intensive care unit cases and the distribution of disease se-
Table 1. Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 at 10 Hospitals (Core Cohort) in Daegu

|                                | Development group | Validation group |       |       |       |       |
|--------------------------------|-------------------|------------------|-------|-------|-------|-------|
|                                | (n=1232)          | (n=1109)         | (n=123) |       |       |       |
|                                | Survival          | Non-survival     |       | Survival | Non-survival |       |
|                                | (n=528)           | (n=483)          | (n=45) |       |       |       |
| **Sex, Female**                | 482 (39.1)        | 410 (37.0)       | 72 (58.5) | 159 (30.1) | 142 (29.4) | 17 (37.8) | 0.316 |
| **Age, yr**                    | 61.0 (48.0–73.0)  | 59.0 (46.0–71.0) | 78.5 (71.0–85.0) | 61.0 (49.0–74.0) | 59.0 (47.0–70.0) | 81.0 (73.0–85.0) | <0.001 |
| **Diabetes**                   |                   | <0.001           |       |       |       |       |
| No                             | 977 (79.3)        | 912 (82.2)       | 65 (52.8) | 443 (83.9) | 414 (85.7) | 29 (64.4) | <0.001 |
| Yes                            | 255 (20.7)        | 197 (17.8)       | 58 (47.2) | 85 (16.1) | 69 (14.3) | 16 (35.6) |       |
| **Heart failure**              |                   | <0.001           |       |       |       |       |
| No                             | 1206 (97.9)       | 1093 (98.6)      | 113 (91.9) | 513 (97.2) | 471 (97.5) | 42 (93.3) |       |
| Yes                            | 26 (2.1)          | 16 (1.4)         | 10 (8.1) | 15 (2.8) | 12 (2.5) | 3 (6.7) |       |
| **Hypertension**               |                   | <0.001           |       |       |       |       |
| No                             | 819 (66.5)        | 771 (69.5)       | 48 (39.0) | 359 (68.0) | 345 (71.4) | 14 (31.1) |       |
| Yes                            | 413 (33.5)        | 338 (30.5)       | 75 (61.0) | 169 (32.0) | 138 (28.6) | 31 (68.9) |       |
| **Asthma**                     | >0.999            | 0.252            |       |       |       |       |
| No                             | 1190 (96.6)       | 1071 (96.6)      | 119 (96.7) | 509 (96.4) | 469 (97.1) | 40 (88.9) |       |
| Yes                            | 42 (3.4)          | 38 (3.4)         | 4 (3.3) | 19 (3.6) | 14 (2.9) | 5 (11.1) |       |
| **COPD**                       | 0.142             | 0.999            |       |       |       |       |
| No                             | 1215 (98.6)       | 1096 (98.8)      | 119 (96.7) | 519 (98.3) | 475 (98.3) | 44 (97.8) |       |
| Yes                            | 17 (1.4)          | 13 (1.2)         | 4 (3.3) | 9 (1.7) | 8 (1.7) | 1 (2.2) |       |
| **Chronic kidney disease**     |                   | <0.001           |       |       |       |       |
| No                             | 1206 (97.9)       | 1094 (98.6)      | 112 (91.1) | 521 (98.7) | 479 (99.2) | 42 (93.3) |       |
| Yes                            | 26 (2.1)          | 15 (1.4)         | 11 (8.9) | 7 (1.3) | 4 (0.8) | 3 (6.7) |       |
| **Cancer**                     | 0.003             | 0.030            |       |       |       |       |
| No                             | 1186 (96.3)       | 1074 (96.8)      | 112 (91.1) | 500 (94.7) | 461 (95.4) | 39 (86.7) |       |
| Yes                            | 46 (3.7)          | 35 (3.2)         | 11 (8.9) | 28 (5.3) | 22 (4.6) | 6 (13.3) |       |
| **Chronic liver disease**      | 0.177             | 0.633            |       |       |       |       |
| No                             | 1214 (98.5)       | 1095 (98.7)      | 119 (96.7) | 517 (97.9) | 472 (97.7) | 45 (100.0) |       |
| Yes                            | 18 (1.5)          | 14 (1.3)         | 4 (3.3) | 11 (2.1) | 11 (2.3) | 0 (0.0) |       |
| **Neurologic disease**         |                   | <0.001           |       |       |       |       |
| No                             | 1220 (99.0)       | 1103 (99.5)      | 117 (95.1) | 526 (99.6) | 481 (99.6) | 45 (100.0) |       |
| Yes                            | 12 (1.0)          | 6 (0.5)          | 6 (4.9) | 2 (0.4) | 2 (0.4) | 0 (0.0) |       |
| **Hematologic disease**        |                   | 0.083            |       |       |       |       |
| No                             | 1217 (98.8)       | 1098 (99.0)      | 119 (96.7) | 525 (99.4) | 480 (99.4) | 45 (100.0) |       |
| Yes                            | 15 (1.2)          | 11 (1.0)         | 4 (3.3) | 3 (0.6) | 3 (0.6) | 0 (0.0) |       |
| **Dementia**                   |                   | <0.001           |       |       |       |       |
| No                             | 1112 (90.3)       | 1032 (93.1)      | 80 (65.0) | 472 (89.4) | 438 (90.7) | 34 (75.6) |       |
| Yes                            | 120 (9.7)         | 77 (6.9)         | 43 (35.0) | 56 (10.6) | 45 (9.3) | 11 (24.4) |       |
| **Psychiatric disease**        | 0.061             | 0.832            |       |       |       |       |
| No                             | 1139 (92.5)       | 1031 (93.0)      | 108 (87.8) | 491 (93.0) | 450 (93.2) | 41 (91.1) |       |
| Yes                            | 93 (7.5)          | 78 (7.0)         | 15 (12.2) | 37 (7.0) | 33 (6.8) | 8 (19.4) |       |
| **Need for O2 supply at admission** | <0.001            | <0.001           |       |       |       |       |
| No                             | 1005 (81.6)       | 964 (86.9)       | 41 (33.3) | 434 (82.2) | 416 (86.1) | 18 (40.0) |       |
| Yes                            | 227 (18.4)        | 145 (13.1)       | 82 (66.7) | 94 (17.8) | 67 (13.9) | 27 (60.0) |       |
| **Body temperature ≥37.5°C**   |                   | <0.001           |       |       |       |       |
| No                             | 964 (78.2)        | 889 (80.2)       | 75 (61.0) | 400 (75.8) | 370 (76.6) | 30 (66.7) | 0.192 |
| Yes                            | 268 (21.8)        | 220 (19.8)       | 48 (39.0) | 128 (24.2) | 113 (23.4) | 15 (33.3) |       |
| **Hospitalization in intensive care unit** | <0.001            | <0.001           |       |       |       |       |
| No                             | 1129 (91.6)       | 1055 (95.1)      | 74 (60.2) | 480 (90.9) | 453 (93.8) | 27 (60.0) |       |
| Yes                            | 103 (8.4)         | 54 (4.9)         | 49 (39.8) | 48 (9.1) | 30 (6.2) | 18 (40.0) |       |
Table 1. Clinical Characteristics and Outcomes of Patients Hospitalized for COVID-19 at 10 Hospitals (Core Cohort) in Daegu (continued)

| Development group | Validation group |
|-------------------|------------------|
| **Total** (n=1232) | **Total** (n=528) |
| **Survival** (n=1109) | **Survival** (n=483) |
| **Non-survival** (n=123) | **Non-survival** (n=45) |
| **p** value | **p** value |

- **Worst severity during hospitalization***: <0.001  <0.001  
  - Mild: 828 (67.2)  828 (74.7)  0 (0.0)  362 (68.6)  360 (74.5)  2 (4.4)  
  - Moderate: 271 (22.0)  257 (23.2)  14 (11.4)  109 (20.6)  106 (21.9)  3 (6.7)  
  - Severe: 33 (2.7)  24 (2.2)  9 (7.3)  18 (3.4)  17 (3.5)  1 (2.2)  
  - Death: 100 (8.1)  0 (0.0)  100 (81.3)  39 (7.4)  0 (0.0)  39 (86.7)  

- **Hemoglobin, g/dL**: 12.6 (11.6–13.8)  12.7 (11.7–13.9)  11.9 (10.2–13.4)  <0.001  12.7 (11.8–13.6)  12.8 (11.9–13.6)  11.8 (10.3–13.1)  0.002  
- **Platelet, ×10^3/μL**: 218.0 (168.0–273.0)  222.0 (173.0–278.0)  176.0 (123.5–224.5)  <0.001  229.0 (172.0–285.0)  234.0 (176.0–286.0)  168.0 (131.0–232.0)  <0.001  
- **White blood cell, ×10^3/μL**: 5.5 (4.3–7.0)  5.4 (4.3–6.8)  6.7 (4.8–9.4)  <0.001  5.7 (4.4–7.3)  5.7 (4.4–7.1)  6.9 (4.4–12.0)  0.007  
- **Aspartate aminotransferase, U/L**: 25.0 (20.0–36.0)  25.0 (19.0–34.0)  41.0 (26.0–63.0)  <0.001  25.0 (20.0–37.0)  25.0 (20.0–35.0)  46.0 (27.0–61.0)  <0.001  
- **Alanine aminotransferase, U/L**: 20.0 (14.0–31.0)  20.0 (14.0–31.0)  21.0 (14.0–36.0)  0.244  20.0 (14.0–30.0)  20.0 (14.0–30.0)  20.0 (14.0–30.0)  <0.001  
- **Blood urea nitrogen, mg/dL**: 13.0 (10.1–17.1)  13.0 (10.0–16.1)  22.0 (15.0–33.5)  <0.001  13.0 (10.0–17.1)  12.7 (10.0–16.2)  20.1 (14.0–31.7)  <0.001  
- **Creatinine, mg/dL**: 0.8 (0.6–0.9)  0.8 (0.6–0.9)  1.0 (0.8–1.6)  <0.001  0.7 (0.6–0.9)  0.7 (0.6–0.9)  1.0 (0.8–1.4)  <0.001  
- **Glucose, mg/dL**: 111.0 (94.0–141.0)  109.0 (94.0–135.0)  142.5 (101.5–189.5)  <0.001  109.0 (93.0–136.0)  107.0 (93.0–131.0)  151.5 (115.0–204.5)  <0.001  
- **C-reactive protein, mg/dL**: 0.6 (0.1–3.8)  0.4 (0.1–2.6)  10.5 (5.3–17.7)  <0.001  0.6 (0.1–3.0)  0.4 (0.1–2.0)  10.0 (4.7–14.9)  <0.001  
- **Lactate dehydrogenase, U/L**: 425.0 (356.0–531.0)  435.0 (354.0–554.0)  424.0 (348.0–538.0)  582.0 (481.0–761.0)  <0.001  
- **Total bilirubin, mg/dL**: 0.5 (0.3–0.7)  0.5 (0.3–0.6)  0.7 (0.4–0.9)  <0.001  0.5 (0.3–0.7)  0.5 (0.3–0.7)  0.4 (0.3–0.7)  0.880  
- **Infiltration on the chest X-rays during initial diagnosis**: <0.001  <0.001  
  - No: 626 (50.8)  594 (53.6)  32 (26.0)  256 (48.5)  249 (51.6)  7 (15.6)  
  - Yes: 606 (49.2)  542 (46.4)  91 (74.0)  272 (51.5)  244 (48.4)  38 (84.4)  

COPD, chronic obstructive pulmonary disease.
Data are presented as n (%) or median (IQR).
*According to the definition of Korean coronavirus disease 2019 response guidelines version 9-5-1, all cases were classified as follows. Mild: no limit of activity but no oxygen supplement; moderate: oxygen with nasal prong or facial mask; severe: oxygen with non-invasive ventilation, high flow oxygen, invasive ventilation, multi-organ failure, extracorporeal membrane oxygenation or continuous renal replacement therapy; and death.

verity were similar in the two groups. In the development group, diabetes (p<0.001), heart failure (p<0.001), hypertension (p<0.001), chronic kidney disease (p<0.001), cancer (p=0.003), neurologic disease (p<0.001), and dementia (p<0.001) showed significantly higher rates in the non-survival subgroups than in the survival subgroups. In the validation group, diabetes (p<0.001), hypertension (p<0.001), chronic kidney disease (p=0.008), cancer (p=0.030), and dementia (p=0.004) showed significantly higher rates in the non-survival subgroups than in the survival subgroups.

Moreover, the laboratory and radiological findings on admission also showed a significant difference between the survival and non-survival subgroups (Table 1). In the development and validation groups, significant factors in the non-survival subgroups were leukocytosis, elevated CRP and LDH levels, and initial infiltration observed on the chest X-rays (p<0.001).

Severe risk factors predicting mortality
In the development group, we analyzed the various factors using a univariate logistic regression analysis and employed Cox proportional hazards regression for the total mortality during the follow-up period (Table 2). To predict mortality, we chose the following cutoff values: age ≥70 years and CRP >4 mg/dL. For the Cox hazards regression analyses, we employed the following factors: age ≥70 years [hazard ratio (HR) 2.490; 95% confidence interval (CI) 1.546–4.007; p<0.001], need for oxygen supply on admission (HR 2.538; 95% CI 1.661–3.878; p<0.001), diabetes (HR 2.116; 95% CI 1.462–3.065; p<0.001), chronic kidney disease (HR 2.348; 95% CI 1.245–4.426; p=0.009), dementia (HR 3.060; 95% CI 2.024–4.627; p<0.001), CRP >4 mg/dL (HR 3.893; 95% CI 2.407–6.296; p<0.001), and infiltration observed in the initial chest X-rays (HR 1.561; 95% CI 1.023–2.381; p=0.039).
We set up the new scale with 10 risk factors for mortality: age ≥70 yr, need for oxygen supply at admission, diabetes, chronic kidney disease, dementia, CRP >4 mg/dL, and infiltration observed in the chest X-rays at the initial diagnosis (Table 2). The scale was established according to the coefficients in the Cox regression analyses. The risk scores ranged from 0 to 16, from lowest to highest risk in the development group. A total of 395 (32.1%) patients scored 0 point on the scale. As the score increased, the number of patients decreased and the mortality rate increased (Supplementary Fig. 1, only online).

**DISCUSSION**

The present study analyzed 1760 patients who were admitted and diagnosed with COVID-19, with a case mortality of 9.54%.17 This study defined a scoring system for predicting mortality us-
We stratified the four risk groups according to the score, identified the initial diagnosis, and need for oxygen supply at admission. Among seven variables: age, diabetes, chronic kidney disease, dementia, CRP >4 mg/dL, infiltration observed on chest X-rays at admission, we highlighted each comorbidity as severity predictor by weighting the points according to Cox hazard regression analysis. As shown in previous studies, CRP was one of the independent risk factors in the Cox hazard regression analysis in this study. High CRP levels reflect inflammation and suggest longer hospital stays and poorer prognosis in COVID-19. Our study results showed that the CRP trend is more closely related to the prognosis in community-acquired pneumonia compared to the initial CRP level. Therefore, further research on mortality and CRP follow-up in early hospitalizations is needed.

In our study, infiltration observed on chest X-rays as a risk factor was consistent with a previous report. Researchers have demonstrated that the Bríxia score based on lesions observed in chest X-rays in COVID-19 pneumonia was likely to show high-risk severity. A worsening Bríxia score and a Bríxia score of >3 on admission are correlated with disease severity and death. Feng et al. found that age, neutrophil-lymphocyte ratio, and chest computed tomography severity score corresponded with severe pneumonia in COVID-19, and developed a nomogram on the risk of severe pneumonia. Given its predictor of severity and mortality, chest X-rays were nonspecific, but low in cost and easy available. Previous studies have supported the use of chest X-rays in scoring systems such as ours, since X-rays have an advantage of easy availability and low cost in predicting COVID-19 severity.

Table 3: Stratified Risk Group by Score and Mortality in the Development and Validation Groups

| Score | Risk group | Development group | Validation group |
|-------|------------|-------------------|------------------|
|       | Number of patients (%) | Number of deaths (%) | Number of patients (%) | Number of deaths (%) |
| 0–3   | Low 682 (55.4) | 9 (0.6) | 298 (56.4) | 1 (0.3) |
| 4–6   | Intermediate 248 (20.1) | 20 (18.4) | 110 (20.8) | 6 (5.5) |
| 7–10  | High 168 (13.6) | 44 (19.4) | 65 (12.3) | 15 (23.1) |
| ≥11   | Very high 134 (10.9) | 106 (50.0) | 55 (10.4) | 23 (41.8) |

Fig. 2. Clinical outcome in risk categories of the study population. (A) Mortality of COVID-19 in risk categories using the prediction model. (B) 28-day mortality for COVID-19 in risk categories using the prediction model.

predictor of 30-day mortality, given that adding CRP levels to the pneumonia severity index did not improve the 30-day mortality; however, the authors were able to show a relationship between CRP levels and radiological grading through multivariate logistic regression analysis. As shown in previous studies, CRP was one of the independent risk factors in the Cox hazard regression analysis in this study. High CRP levels reflect inflammation and suggest longer hospital stays and poorer prognosis in COVID-19. However, previous studies have shown that the CRP trend is more closely related to the prognosis in community-acquired pneumonia compared to the initial CRP level. Therefore, further research on mortality and CRP follow-up in early hospitalizations is needed.

In our study, infiltration observed on chest X-rays as a risk factor was consistent with a previous report. Researchers have demonstrated that the Bríxia score based on lesions observed in chest X-rays in COVID-19 pneumonia was likely to show high-risk severity. A worsening Bríxia score and a Bríxia score of >3 on admission are correlated with disease severity and death. Feng et al. found that age, neutrophil-lymphocyte ratio, and chest computed tomography severity score corresponded with severe pneumonia in COVID-19, and developed a nomogram on the risk of severe pneumonia. Given its predictor of severity and mortality, chest X-rays were nonspecific, but low in cost and easy available. Previous studies have supported the use of chest X-rays in scoring systems such as ours, since X-rays have an advantage of easy availability and low cost in predicting COVID-19 severity.

We highlighted each comorbidity as severity predictor by weighting the points according to Cox hazard regression analyses. Guan et al. stated that having one or more comorbidity was correlated to poor clinical outcomes (one comorbidity vs. two or more comorbidities: HR 1.79, 95% CI 1.16–2.77 vs. HR 2.59, 95% CI 1.61–4.17). Given the results of various studies from weighting each score for separate medical conditions, individualizing the variables will likely help predict mortality in COVID-19. Our study results showed that diabetes and chronic kidney disease were associated with COVID-19 severity, which was similar to the findings of previous studies. Wang et al. demonstrated that a high glycosylated hemoglobin level could lead to hyperinflammation and hypercoagulability. Given that the data collection period included an outbreak at the psychiatric hospital, the dementia score was...
3 points in our study, which might have biased the results to a larger proportion of dementia cases. The mechanism behind dementia and disease progression in COVID-19 remains unclear, but we believe that the patients with dementia had difficulty accessing medical facilities and were living in an enclosed environment. Our study’s main strengths are the high sensitivity and specificity values as well as the high accuracy using easily accessible variables. There have been several studies exploring new scoring systems. The CALL scoring system for predicting disease progression employs age, comorbidities, lymphocyte counts, and serum LDH levels with an AUC of 0.91 (95% CI 0.86–0.94), but it has shown certain limitations due to its relatively low accuracy for determining disease progression in a validation study. A previous study in the Bronx, New York, divided 4711 patients into derivation and validation groups, and then created a scoring system based on age, oxygen saturation, mean arterial pressure, blood urea nitrogen and CRP levels, and the international normalized ratio. Due to the COVID-19 surge, the study showed a higher mortality rate (23%) than the 7.9% in our study. Gue, et al. suggested a novel score using a modified sepsis-induced coagulopathy score, age, and sex. The authors showed that a score of ≥4 indicated a 7.6-fold greater risk for 30-day mortality. The scale is a simple and easy-to-use calculator, but it tends to have limitations with small samples. The GRAM score, which was applied to 1590 patients hospitalized with COVID-19, was similar to our scoring system in that it employed comorbidities, CRP levels, and chest X-rays to predict critical illness. However, since the GRAM score is a web-based scoring system, accessibility is limited. In contrast, our scoring system has the advantage of being highly accessible, as it uses routine laboratory and radiological results and calculates the points corresponding to each variable.

To our knowledge, there has been no new scoring system that includes separate comorbidities and CRP levels. With its high sensitivity, specificity, and accuracy, the scale classifies low-risk and high-risk patients and allocates them to the appropriate medical centers. As a result, the use of medical resources can be optimized, and the unnecessary transfer and transport of patients can be reduced.

This study had certain limitations. First, given that the patients were recruited in Daegu, South Korea, this study should be carefully considered for generalization, and its scoring system should be tested with large samples and further validation. Second, since this was a retrospective cohort study, we cannot rule out information bias and confounders. However, the selection bias should be minimal as we included all confirmed patients who contracted the disease in an urban setting for a specific period. Third, given that the guidelines for COVID-19 treatment were uncertain and the fact that consistent treatment was not applied, the mortality rates might differ depending on each hospital’s treatment method. Nevertheless, we believe that this study can help predict mortality by using demographic and simple radiological findings, thereby helping to manage inpatients with COVID-19.

In conclusion, we propose a new risk scoring system to predict COVID-19 mortality based on clinical characteristics, CRP levels, and chest X-ray results. Predicting the clinical outcomes for mortality and discharge could help assign patients to the appropriate medical facilities and match each patient with the appropriate management, for as long as the pandemic persists.

AUTHOR CONTRIBUTIONS

Conceptualization: Sohyun Bae and Shin-Woo Kim. Data curation: Sohyun Bae, Hyun-Ha Chang, and Shin-Woo Kim. Formal analysis: Sohyun Bae, Hyun-Ha Chang, and Shin-Woo Kim. Funding acquisition: Shin-Woo Kim. Investigation: Yoonjung Kim, Soyoon Hwang, and KI Tae Kwon. Methodology: KI Tae Kwon and Hyun-Ha Chang. Project administration: all authors. Resources: Shin-Woo Kim. Software: Shin-Woo Kim. Supervision: Shin-Woo Kim. Validation: Yoonjung Kim and Soyoon Hwang. Visualization: Sohyun Bae and Shin-Woo Kim. Writing—original draft: Sohyun Bae. Writing—review & editing: Hyun-Ha Chang and Shin-Woo Kim. Approval of final manuscript: all authors.

ORCID iDs

Sohyun Bae https://orcid.org/0000-0002-0206-7108
Yoonjung Kim https://orcid.org/0000-0002-7454-4014
Soyoon Hwang https://orcid.org/0000-0003-3618-174X
KI Tae Kwon https://orcid.org/0000-0003-4666-0672
Hyun-Ha Chang https://orcid.org/0000-0002-9405-2121
Shin-Woo Kim https://orcid.org/0000-0002-3755-8249

REFERENCES

1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395:497-506.
2. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19—final report. N Engl J Med 2020;383:1813-26.
3. Cohen MS. Monoclonal antibodies to disrupt progression of early COVID-19 infection. N Engl J Med 2021;384:289-91.
4. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, Cinnamont K, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with COVID-19. N Engl J Med 2021;384:693-704.
5. Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with COVID-19. N Engl J Med 2021;384:795-807.
6. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 patients in Wuhan. J Allergy Clin Immunol 2020;146:110-8.
7. Lee JY, Kim HA, Huh K, Hyun M, Rhee JY, Jang S, et al. Risk factors for mortality and respiratory support in elderly patients hospitalized with COVID-19 in Korea. J Korean Med Sci 2020;35:e223.
8. Fang L, Karakulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 2020;8:e21.
9. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities associated with mortality in 31,461 adults with COVID-19.
VID-19 in the United States: a federated electronic medical record analysis. PLoS Med 2020;17:e1003321.

10. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395:1054-62.

11. Kermali M, Khalsa RK, Pillai K, Ismail Z, Harky A. The role of biomarkers in diagnosis of COVID-19: a systematic review. Life Sci 2020;254:117788.

12. Shang Y, Liu T, Wei Y, Li J, Shao L, Liu M, et al. Scoring systems for predicting mortality for severe patients with COVID-19. EclinicalMedicine 2020;24:100426.

13. Zhang C, Qin L, Li K, Wang Q, Zhao Y, Xu B, et al. A novel scoring system for prediction of disease severity in COVID-19. Front Cell Infect Microbiol 2020;10:318.

14. Mancilla-Galindo J, Vera-Zertuche JM, Navarro-Cruz AR, Segura-Badilla O, Reyes-Velázquez G, Tepepa-López FJ, et al. Development and validation of the patient history COVID-19 (PH-Covi9) scoring system: a multivariable prediction model of death in Mexican patients with COVID-19. Epidemiol Infect 2020;148:e286.

15. Jang JG, Hur J, Hong KS, Lee W, Ahn JH. Prognostic accuracy of the SIRS, qSOFa, and NEWS for early detection of clinical deterioration in SARS-CoV-2 infected patients. J Korean Med Sci 2020;35:e234.

16. Kodama T, Obinata H, Mori H, Murakami W, Suyama Y, Sasaki H, et al. Prediction of an increase in oxygen requirement of SARS-CoV-2 pneumonia using three different scoring systems. J Infect Chemother 2021;27:336-41.

17. Kim SW, Kim SM, Kim YK, Kim JY, Lee YM, Kim BO, et al. Clinical characteristics and outcomes of COVID-19 cohort patients in Daegu metropolitan city outbreak in 2020. J Korean Med Sci 2021;36:e12.

18. Chen W, Zheng KI, Liu S, Yan Z, Xu C, Qiao Z. Plasma CRP level is positively associated with the severity of COVID-19. Ann Clin Microbiol Antimicrob 2020;19:18.

19. Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, et al. Prognostic value of C-reactive protein in patients with coronavirus 2019. Clin Infect Dis 2020;71:2174-9.

20. Satici C, Demirkol MA, Sargin Altunok E, Guroy B, Alkan M, Kamar S, et al. Performance of pneumonia severity index and CURB-65 in predicting 30-day mortality in patients with COVID-19. Int J Infect Dis 2020;98:84-9.

21. Guo S, Mao X, Liang M. The moderate predictive value of serial serum CRP and PCT levels for the prognosis of hospitalized community-acquired pneumonia. Respir Rev 2018;19:193.

22. Borghesi A, Zigliani A, Golemi S, Carapella N, Maculotti P, Farina D, et al. Chest X-ray severity index as a predictor of in-hospital mortality in coronavirus disease 2019: a study of 302 patients from Italy. Int J Infect Dis 2020;96:291-3.

23. Borghesi A, Maroldi R. COVID-19 outbreak in Italy: experimental chest X-ray scoring system for quantifying and monitoring disease progression. Radiol Med 2020;125:509-13.

24. Maroldi R, Rondi P, Agazzi GM, Ravanelli M, Borghesi A, Farina D. Which role for chest X-ray score in predicting the outcome in COVID-19 pneumonia? Eur Radiol 2021;31:4016-22.

25. Feng Z, Yu Q, Yao S, Luo L, Zhou W, Mao X, et al. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nat Commun 2020;11:4968.

26. Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, Li YM, et al. Comorbidity and its impact on 1,590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J 2020;55:2000547.

27. King JT Jr, Yoon JS, Rentisch CT, Tate JP, Park LS, Kidwai-Khan F, et al. Development and validation of a 30-day mortality index based on pre-existing medical administrative data from 13,323 COVID-19 patients: the Veterans Health Administration COVID-19 (VACO) index. PLoS One 2020;15:e0241825.

28. Wang Z, Du Z, Zhu F. Glycosylated hemoglobin is associated with systemic inflammation, hypercoagulability, and prognosis of COVID-19 patients. Diabetes Res Clin Pract 2020;164:108214.

29. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int 2020;97:829-38.

30. Chen D, Hu C, Su F, Song Q, Wang Z. Exposure to SARS-CoV-2 in a high transmission setting increases the risk of severe COVID-19 compared with exposure to a low transmission setting? J Travel Med 2020;27:taaa094.

31. Ji D, Zhang D, Xu J, Chen Z, Yang T, Zhao P, et al. Prediction for progression risk in patients with COVID-19 pneumonia: the CALL score. Clin Infect Dis 2020;71:1393-9.

32. Grifoni E, Valoriani A, Cei F, Vannucchi V, Moroni F, Pelagatti L, et al. The CALL score for predicting outcomes in patients with COVID-19. Clin Infect Dis 2021;72:182-3.

33. Altschul DJ, Unda SR, Benton J, de la Garza Ramos R, Cezayirli P, Mehler M, et al. A novel severity score to predict inpatient mortality in COVID-19 patients. Sci Rep 2020;10:16726.

34. Gue YX, Tennyson M, Gao J, Ren S, Kanji R, Gorog DA. Development of a novel risk score to predict mortality in patients admitted to hospital with COVID-19. Sci Rep 2020;10:21379.

35. Liang W, Liang H, Ou L, Chen B, Chen A, Li C, et al. Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19. JAMA Intern Med 2020;180:1081-9.